Stocktoria
ROCKET PHARMACEUTICALS, INC. RCKT
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2015-02-18
ROCKET PHARMACEUTICALS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $142.0M | $171.2M | $186.3M | $165.6M | $125.5M |
| Operating income | -$231.7M | -$273.2M | -$259.7M | -$224.3M | -$167.2M |
| Interest expense | $1.9M | $1.9M | $1.9M | $1.9M | $3.0M |
| Income tax | $0 | $0 | $0 | — | — |
| Net income | -$223.1M | -$258.7M | -$245.6M | -$221.9M | -$169.1M |
| EPS (diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 |
| Operating cash flow | -$190.0M | -$209.7M | -$194.9M | -$178.1M | -$121.2M |
| Free cash flow | -$190.5M | -$215.6M | -$211.4M | -$186.5M | -$128.8M |
| Cash & equivalents | $77.6M | $163.6M | $55.9M | $140.5M | $232.7M |
| Total assets | $330.4M | $527.7M | $566.3M | $551.8M | $497.0M |
| Total liabilities | $53.2M | $64.5M | $73.8M | $62.1M | $42.3M |
| Shareholders' equity | $277.2M | $463.2M | $492.6M | $489.7M | $454.7M |
Source: SEC EDGAR filings · CIK 0001281895 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.